Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Natural Products Journal, The
  4. Fast Track Articles
  5. Fast Track Article
image of Exploring Pharmacological Mechanisms, Clinical Trials and Patent Landscapes of Berberine: A Review

Abstract

Traditional Chinese medicine has used berberine (BBR) for a long time. Berberine is a natural compound found in several plants, including Royle, DC, Palib., L., , (Fort.) Carr., and L. Berberine is believed to help treat many diseases, such as ovarian and colorectal cancer, high blood pressure, Parkinson's and Alzheimer's disease, diabetes, heart disorders, depression, viral infections, and inflammatory diseases. However, when taken orally, berberine quickly breaks down in the body, leading to low levels in the bloodstream. This means that its absorption in the intestines is limited, which reduces its effectiveness despite its potential health benefits. The liver is the main organ that processes and uses berberine in both animals and humans, and about 84% of berberine and its byproducts are excreted in the feces. We thoroughly reviewed the available research on berberine from reliable sources like PubMed, ScienceDirect, ClinicalTrials.gov, and Scopus. Our study summarizes the latest findings on the therapeutic benefits of berberine and provides updated information on clinical research and patents. This review covers the various pharmacological effects of berberine, including its use in treating Alzheimer's disease, high blood pressure, neuroprotective effects, anti-arrhythmia, Parkinson's disease, diabetes, cancer, and depression.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/npj/10.2174/0122103155324599241028163050
2024-11-04
2025-06-24

  • From This Site

    /content/journals/npj/10.2174/0122103155324599241028163050
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Qin Z. Tang R. Liang J. Jia X. Berberine, a natural alkaloid: Advances in its pharmacological effects and mechanisms in the treatment of autoimmune diseases. Int. Immunopharmacol. 2024 137 112422 10.1016/j.intimp.2024.112422 38880024
    [Google Scholar]
  2. Yazdanpanah E. Dadfar S. Shadab A. Orooji N. Nemati M. Pazoki A. Esmaeili S.A. Baharlou R. Haghmorad D. Berberine: A natural modulator of immune cells in multiple sclerosis. Immun. Inflamm. Dis. 2024 12 3 e1213 10.1002/iid3.1213 38477663
    [Google Scholar]
  3. Xia L.M. Luo M.H. Study progress of berberine for treating cardiovascular disease. Chronic Dis. Transl. Med. 2016 1 4 231 235 29063012
    [Google Scholar]
  4. Imenshahidi M. Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): A clinical review. Phytother. Res. 2019 33 3 504 523 10.1002/ptr.6252 30637820
    [Google Scholar]
  5. Cui Y. Zhou Q. Jin M. Jiang S. Shang P. Dong X. Li L. Research progress on pharmacological effects and bioavailability of berberine. Naunyn Schmiedebergs Arch. Pharmacol. 2024 10.1007/s00210‑024‑03199‑0 38888754
    [Google Scholar]
  6. Ma X. Yu X. Li R. Cui J. Yu H. Ren L. Jiang J. Zhang W. Wang L. Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism. J. Ethnopharmacol. 2024 319 Pt 2 117238 10.1016/j.jep.2023.117238 37774895
    [Google Scholar]
  7. Ye Y. Liu X. Wu N. Han Y. Wang J. Yu Y. Chen Q. Efficacy and safety of berberine alone for several metabolic disorders: A systematic review and meta-analysis of randomized clinical trials. Front. Pharmacol. 2021 12 653887 10.3389/fphar.2021.653887 33981233
    [Google Scholar]
  8. Yu H. Zhang S. Li R. Ma C. Zhang Q. Xia F. Zhou B. Xie Z. Liao Z. Berberine alleviates inflammation and suppresses PLA2-COX-2-PGE2-EP2 pathway through targeting gut microbiota in DSS-induced ulcerative colitis. Biochem. Biophys. Res. Commun. 2024 695 149411 10.1016/j.bbrc.2023.149411 38154262
    [Google Scholar]
  9. Suadoni M.T. Atherton I. Berberine for the treatment of hypertension: A systematic review. Complement. Ther. Clin. Pract. 2021 42 101287 10.1016/j.ctcp.2020.101287 33461163
    [Google Scholar]
  10. Meng F.C. Wu Z.F. Yin Z.Q. Lin L.G. Wang R. Zhang Q.W. Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity. Chin. Med. 2018 13 1 13 10.1186/s13020‑018‑0171‑3 29541156
    [Google Scholar]
  11. Wang J. Wang L. Lou G.H. Zeng H.R. Hu J. Huang Q.W. Peng W. Yang X.B. Coptidis Rhizoma: A comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Pharm. Biol. 2019 57 1 193 225 10.1080/13880209.2019.1577466 30963783
    [Google Scholar]
  12. Gao Y. Nie K. Wang H. Dong H. Tang Y. Research progress on antidepressant effects and mechanisms of berberine. Front. Pharmacol. 2024 15 1331440 10.3389/fphar.2024.1331440 38318145
    [Google Scholar]
  13. Davoodvandi A. Sadeghi S. Alavi S.M.A. Alavi S.S. Jafari A. Khan H. Aschner M. Mirzaei H. Sharifi M. Asemi Z. The therapeutic effects of berberine for gastrointestinal cancers. Asia Pac. J. Clin. Oncol. 2024 20 2 152 167 10.1111/ajco.13941 36915942
    [Google Scholar]
  14. Liang Y. Xu X. Yin M. Zhang Y. Huang L. Chen R. Ni J. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: A systematic literature review and a meta-analysis. Endocr. J. 2019 66 1 51 63 10.1507/endocrj.EJ18‑0109 30393248
    [Google Scholar]
  15. Pang B. Zhao L.H. Zhou Q. Zhao T.Y. Wang H. Gu C.J. Tong X.L. Application of berberine on treating type 2 diabetes mellitus. Int. J. Endocrinol. 2015 2015 905749 10.1155/2015/905749
    [Google Scholar]
  16. Kim S. Lee S.Y. Cho H.J. Berberine and zinc oxide-based nanoparticles for the chemo-photothermal therapy of lung adenocarcinoma. Biochem. Biophys. Res. Commun. 2018 501 3 765 770 10.1016/j.bbrc.2018.05.063 29758197
    [Google Scholar]
  17. Cazzaniga M. Bonanni B. Relationship between metabolic disorders and breast cancer incidence and outcomes. Is there a preventive and therapeutic role for berberine? Anticancer Res. 2018 38 8 4393 4402 10.21873/anticanres.12741 30061203
    [Google Scholar]
  18. Li J. Tian Y. Zhao L. Wang Y. Zhang H. Xu D. Zhao X. Li Y. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells. Asian J. Androl. 2016 18 4 607 612 10.4103/1008‑682X.169997 26698234
    [Google Scholar]
  19. Wen B. Huang C. Wu L. Liu H. Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer. OncoTargets Ther. 2016 9 4121 4127 10.2147/OTT.S104729 27462166
    [Google Scholar]
  20. Hu Q. Li L. Zou X. Xu L. Yi P. Berberine attenuated proliferation, invasion and migration by targeting the AMPK/HNF4α/WNT5A pathway in gastric carcinoma. Front. Pharmacol. 2018 9 1150 10.3389/fphar.2018.01150 30405404
    [Google Scholar]
  21. Behl T. Singh S. Sharma N. Zahoor I. Albarrati A. Albratty M. Meraya A.M. Najmi A. Bungau S. Expatiating the pharmacological and nanotechnological aspects of the alkaloidal drug berberine: Current and future trends. Molecules 2022 27 12 3705 10.3390/molecules27123705 35744831
    [Google Scholar]
  22. Cicero A.F. Baggioni A. Berberine and its role in chronic disease. Anti-inflammatory Nutraceuticals and Chronic Diseases 2016 27 45 Springer Cham Gupta S. Prasad S. Aggarwal B. 10.1007/978‑3‑319‑41334‑1_2
    [Google Scholar]
  23. Ionita-Radu F. Patoni C. Nancoff A.S. Marin F.S. Gaman L. Bucurica A. Socol C. Jinga M. Dutu M. Bucurica S. Berberine effects in pre-fibrotic stages of non-alcoholic fatty liver disease - Clinical and pre-clinical overview and systematic review of the literature. Int. J. Mol. Sci. 2024 25 8 4201 10.3390/ijms25084201 38673787
    [Google Scholar]
  24. Song L. Zhang W. Tang S. Luo S. Xiong P. Liu J. Hu H. Chen Y. Jia B. Yan Q. Tang S. Huang W. Natural products in traditional Chinese medicine: Molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems. Biomed. Pharmacother. 2024 170 116039 10.1016/j.biopha.2023.116039 38157643
    [Google Scholar]
  25. Kumar A. Ekavali Chopra K. Mukherjee M. Pottabathini R. Dhull D.K. Current knowledge and pharmacological profile of berberine: An update. Eur. J. Pharmacol. 2015 761 288 297 10.1016/j.ejphar.2015.05.068 26092760
    [Google Scholar]
  26. Ma J.Y. Feng R. Tan X.S. Ma C. Shou J.W. Fu J. Huang M. He C.Y. Chen S.N. Zhao Z.X. He W.Y. Wang Y. Jiang J.D. Excretion of berberine and its metabolites in oral administration in rats. J. Pharm. Sci. 2013 102 11 4181 4192 10.1002/jps.23718 24006193
    [Google Scholar]
  27. Liu C.S. Zheng Y.R. Zhang Y.F. Long X.Y. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia 2016 109 274 282 10.1016/j.fitote.2016.02.001 26851175
    [Google Scholar]
  28. He J.M. Mu Q. The medicinal uses of the genus Mahonia in traditional Chinese medicine: An ethnopharmacological, phytochemical and pharmacological review. J. Ethnopharmacol. 2015 175 668 683 10.1016/j.jep.2015.09.013 26387740
    [Google Scholar]
  29. Mughal T.A. Ali S. Mumtaz S. Summer M. Saleem M.Z. Hassan A. Hameed M.U. Evaluating the biological (antidiabetic) potential of TEM, FTIR, XRD, and UV-spectra observed Berberis lyceum conjugated silver nanoparticles. Microsc. Res. Tech. 2024 87 6 1286 1305 10.1002/jemt.24509 38351883
    [Google Scholar]
  30. Hussain N. Adhikari A. Ahmad M.S. Wahab A. Ali M. Choudhary M.I. Two new prenylated flavonoids from the roots of Berberis thunbergii DC. Nat. Prod. Res. 2017 31 7 785 790 10.1080/14786419.2016.1244195 27788592
    [Google Scholar]
  31. Laamech J. El-Hilaly J. Fetoui H. Chtourou Y. Gouitaa H. Tahraoui A. Lyoussi B. Berberis vulgaris L. effects on oxidative stress and liver injury in lead-intoxicated mice. J. Complement. Integr. Med. 2017 14 1 20150079 10.1515/jcim‑2015‑0079 28195545
    [Google Scholar]
  32. Lee H.Y. He X. Ahn J. Enhancement of antimicrobial and antimutagenic activities of Korean barberry (Berberis koreana Palib.) by the combined process of high‐pressure extraction with probiotic fermentation. J. Sci. Food Agric. 2010 90 14 2399 2404 10.1002/jsfa.4098 20672332
    [Google Scholar]
  33. Dan Y. Liu Y. Peng Y. Qian Z. Xiao P. New collection of crude drugs in Chinese pharmacopoeia 2010 II. Sankezhen (Berberis spp.). Chin. Herb. Med. 2011 3 4 268 284 10.3969/j.issn.1674‑6384.2011.04.006
    [Google Scholar]
  34. Gilca M. Gaman L. Panait E. Stoian I. Atanasiu V. Chelidonium majus - An integrative review: Traditional knowledge versus modern findings. Forsch. Komplement. Med. 2010 17 5 241 248 10.1159/000321397 20980763
    [Google Scholar]
  35. Chen M.L. Xian Y.F. Ip S.P. Tsai S.H. Yang J.Y. Che C.T. Chemical and biological differentiation of cortex phellodendri chinensis and cortex phellodendri amurensis. Planta Med. 2010 76 14 1530 1535 10.1055/s‑0030‑1249774 20354951
    [Google Scholar]
  36. Tang J. Feng Y. Tsao S. Wang N. Curtain R. Wang Y. Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J. Ethnopharmacol. 2009 126 1 5 17 10.1016/j.jep.2009.08.009 19686830
    [Google Scholar]
  37. Tsang C.M. Lau E.P. Di K. Cheung P.Y. Hau P.M. Ching Y.P. Wong Y.C. Cheung A.L. Wan T.S. Tong Y. Tsao S.W. Feng Y. Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int. J. Mol. Med. 2009 24 1 131 138 19513545
    [Google Scholar]
  38. Chen Y.X. Gao Q.Y. Zou T.H. Wang B.M. Liu S.D. Sheng J.Q. Ren J.L. Zou X.P. Liu Z.J. Song Y.Y. Xiao B. Sun X.M. Dou X.T. Cao H.L. Yang X.N. Li N. Kang Q. Zhu W. Xu H.Z. Chen H.M. Cao X.C. Fang J.Y. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: A multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol. Hepatol. 2020 5 3 267 275 10.1016/S2468‑1253(19)30409‑1 31926918
    [Google Scholar]
  39. Torre L.A. Trabert B. DeSantis C.E. Miller K.D. Samimi G. Runowicz C.D. Gaudet M.M. Jemal A. Siegel R.L. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 2018 68 4 284 296 10.3322/caac.21456 29809280
    [Google Scholar]
  40. Bast R.C. Jr Matulonis U.A. Sood A.K. Ahmed A.A. Amobi A.E. Balkwill F.R. Wielgos-Bonvallet M. Bowtell D.D.L. Brenton J.D. Brugge J.S. Coleman R.L. Draetta G.F. Doberstein K. Drapkin R.I. Eckert M.A. Edwards R.P. Elias K.M. Ennis D. Futreal A. Gershenson D.M. Greenberg R.A. Huntsman D.G. Ji J.X.Y. Kohn E.C. Iavarone C. Lengyel E.R. Levine D.A. Lord C.J. Lu Z. Mills G.B. Modugno F. Nelson B.H. Odunsi K. Pilsworth J.A. Rottapel R.K. Powell D.J. Jr Shen L. Shih I.M. Spriggs D.R. Walton J. Zhang K. Zhang R. Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer 2019 125 12 1963 1972 10.1002/cncr.32004 30835824
    [Google Scholar]
  41. Menees S. Saad R. Chey W.D. Agents that act luminally to treat diarrhoea and constipation. Nat. Rev. Gastroenterol. Hepatol. 2012 9 11 661 674 10.1038/nrgastro.2012.162 22945441
    [Google Scholar]
  42. Kong W.J. Zhang H. Song D.Q. Xue R. Zhao W. Wei J. Wang Y.M. Shan N. Zhou Z.X. Yang P. You X.F. Li Z.R. Si S.Y. Zhao L.X. Pan H.N. Jiang J.D. Berberine reduces insulin resistance through protein kinase C–dependent up-regulation of insulin receptor expression. Metabolism 2009 58 1 109 119 10.1016/j.metabol.2008.08.013 19059538
    [Google Scholar]
  43. Singh I.P. Mahajan S. Berberine and its derivatives: A patent review (2009 – 2012). Expert Opin. Ther. Pat. 2013 23 2 215 231 10.1517/13543776.2013.746314 23231038
    [Google Scholar]
  44. Huang Y. Wang K. Gu C. Yu G. Zhao D. Mai W. Zhong Y. Liu S. Nie Y. Yang H. Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib. Oncol. Rep. 2018 40 3 1525 1532 10.3892/or.2018.6552 30015938
    [Google Scholar]
  45. Liu Q. Xu X. Zhao M. Wei Z. Li X. Zhang X. Liu Z. Gong Y. Shao C. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. Mol. Cancer Ther. 2015 14 2 355 363 10.1158/1535‑7163.MCT‑14‑0634 25504754
    [Google Scholar]
  46. Kim S. You D. Jeong Y. Yu J. Kim S.W. Nam S.J. Lee J.E. Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. Phytomedicine 2018 50 43 49 10.1016/j.phymed.2018.08.004 30466991
    [Google Scholar]
  47. Jin P. Zhang C. Li N. Berberine exhibits antitumor effects in human ovarian cancer cells. Anticancer Agents Med. Chem. 15 4 2015 511 516 10.2174/1871520614666141226124110
    [Google Scholar]
  48. Chen Q. Qin R. Fang Y. Li H. Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell. Physiol. Biochem. 2015 36 3 956 965 10.1159/000430270 26087719
    [Google Scholar]
  49. Marverti G. Ligabue A. Lombardi P. Ferrari S. Monti M.G. Frassineti C. Costi M.P. Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. Int. J. Oncol. 2013 43 4 1269 1280 10.3892/ijo.2013.2045 23903781
    [Google Scholar]
  50. Liu L. Fan J. Ai G. Liu J. Luo N. Li C. Cheng Z. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol. Res. 2019 52 1 37 10.1186/s40659‑019‑0243‑6 31319879
    [Google Scholar]
  51. Diabetes atlas. 2003 Available from: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=63f76c94a6a5b64dc29eaa883830907934b1b2ef
  52. Chang W. Chen L. Hatch G.M. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem. Cell Biol. 2015 93 5 479 486 10.1139/bcb‑2014‑0107 25607236
    [Google Scholar]
  53. Yang W.L. Zhang C.Y. Ji W.Y. Zhao L.L. Yang F.Y. Zhang L. Cao X. Berberine metabolites stimulate GLP-1 secretion by alleviating oxidative stress and mitochondrial dysfunction. Am. J. Chin. Med. 2024 52 1 253 274 10.1142/S0192415X24500113 38351702
    [Google Scholar]
  54. Lan J. Zhao Y. Dong F. Yan Z. Zheng W. Fan J. Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J. Ethnopharmacol. 2015 161 69 81 10.1016/j.jep.2014.09.049 25498346
    [Google Scholar]
  55. Cicero A.F.G. Fogacci F. Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: An evidence based approach. Food Funct. 2017 8 6 2076 2088 10.1039/C7FO00178A 28541356
    [Google Scholar]
  56. Caliceti C. Franco P. Spinozzi S. Roda A. Cicero A.F. FG Cicero A. Berberine: New insights from pharmacological aspects to clinical evidences in the management of metabolic disorders. Curr. Med. Chem. 2016 23 14 1460 1476 10.2174/0929867323666160411143314 27063256
    [Google Scholar]
  57. Luo J. Gu Y. Liu P. Jiang X. Yu W. Ye P. Chao Y. Yang H. Zhu L. Zhou L. Chen S. Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both in vivo and in vitro. J. Cell. Physiol. 2018 233 12 9750 9762 10.1002/jcp.26940 30078229
    [Google Scholar]
  58. Shen J. Ma L. Hu C. Pei Y. Jin S. Fang X. Li Y. Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice. Neurosci. Lett. 2016 614 77 82 10.1016/j.neulet.2016.01.002 26773864
    [Google Scholar]
  59. Barangi S. Hayes A.W. Karimi G. The more effective treatment of atrial fibrillation applying the natural compounds; As NADPH oxidase and ion channel inhibitors. Crit. Rev. Food Sci. Nutr. 2018 58 7 1230 1241 10.1080/10408398.2017.1379000 28925721
    [Google Scholar]
  60. Chen C. Yu Z. Li Y. Fichna J. Storr M. Effects of berberine in the gastrointestinal tract - A review of actions and therapeutic implications. Am. J. Chin. Med. 2014 42 5 1053 1070 10.1142/S0192415X14500669 25183302
    [Google Scholar]
  61. Bae J. Lee D. Kim Y.K. Gil M. Lee J.Y. Lee K.J. Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol. Cells 2013 35 2 151 157 10.1007/s10059‑013‑2298‑5 23329300
    [Google Scholar]
  62. Zhang C. Li C. Chen S. Li Z. Jia X. Wang K. Bao J. Liang Y. Wang X. Chen M. Li P. Su H. Wan J.B. Lee S.M.Y. Liu K. He C. Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways. Redox Biol. 2017 11 1 11 10.1016/j.redox.2016.10.019 27835779
    [Google Scholar]
  63. Sadraie S. Kiasalari Z. Razavian M. Azimi S. Sedighnejad L. Afshin-Majd S. Baluchnejadmojarad T. Roghani M. Berberine ameliorates lipopolysaccharide-induced learning and memory deficit in the rat: Insights into underlying molecular mechanisms. Metab. Brain Dis. 2019 34 1 245 255 10.1007/s11011‑018‑0349‑5 30456649
    [Google Scholar]
  64. Khezri M.R. Mohammadipanah S. Ghasemnejad-Berenji M. The pharmacological effects of Berberine and its therapeutic potential in different diseases: Role of the phosphatidylinositol 3‐kinase/AKT signaling pathway. Phytother. Res. 2024 38 1 349 367 10.1002/ptr.8040 37922566
    [Google Scholar]
  65. Deng H. Ma Z. Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice. Food Funct. 2021 12 18 8366 8375 10.1039/D1FO01360B 34342315
    [Google Scholar]
  66. Cai Z. Wang C. Yang W. Role of berberine in Alzheimer’s disease. Neuropsychiatr. Dis. Treat. 2016 12 2509 2520 10.2147/NDT.S114846 27757035
    [Google Scholar]
  67. Nattel S. Dobrev D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nat. Rev. Cardiol. 2016 13 10 575 590 10.1038/nrcardio.2016.118 27489190
    [Google Scholar]
  68. Singh A.K. Singh S.K. Nandi M.K. Mishra G. Maurya A. Rai A. Rai G.K. Awasthi R. Sharma B. Kulkarni G.T. Berberine: A plant-derived alkaloid with therapeutic potential to combat Alzheimer’s disease. Cent. Nerv. Syst. Agents Med. Chem. 2019 19 3 154 170 10.2174/1871524919666190820160053
    [Google Scholar]
  69. Akbar M. Shabbir A. Rehman K. Akash M.S.H. Shah M.A. Neuroprotective potential of berberine in modulating Alzheimer’s disease via multiple signaling pathways. J. Food Biochem. 2021 45 10 e13936 10.1111/jfbc.13936 34523148
    [Google Scholar]
  70. Sun C. Dong S. Chen W. Li J. Luo E. Ji J. Berberine alleviates Alzheimer’s disease by regulating the gut microenvironment, restoring the gut barrier and brain-gut axis balance. Phytomedicine 2024 129 155624 10.1016/j.phymed.2024.155624 38678955
    [Google Scholar]
  71. Matuszyk M.M. Garwood C.J. Ferraiuolo L. Simpson J.E. Staniforth R.A. Wharton S.B. Biological and methodological complexities of beta‐amyloid peptide: Implications for Alzheimer’s disease research. J. Neurochem. 2022 160 4 434 453 10.1111/jnc.15538 34767256
    [Google Scholar]
  72. Kalia L.V. Lang A.E. Parkinson’s disease. Lancet 2015 386 9996 896 912 10.1016/S0140‑6736(14)61393‑3 25904081
    [Google Scholar]
  73. Hou Y. Dan X. Babbar M. Wei Y. Hasselbalch S.G. Croteau D.L. Bohr V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019 15 10 565 581 10.1038/s41582‑019‑0244‑7 31501588
    [Google Scholar]
  74. Cheng Z. Kang C. Che S. Su J. Sun Q. Ge T. Guo Y. Lv J. Sun Z. Yang W. Li B. Li X. Cui R. Berberine: A promising treatment for neurodegenerative diseases. Front. Pharmacol. 2022 13 845591 10.3389/fphar.2022.845591 35668943
    [Google Scholar]
  75. Shin K.S. Choi H.S. Zhao T.T. Suh K.H. Kwon I.H. Choi S.O. Lee M.K. Neurotoxic effects of berberine on long-term l-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Arch. Pharm. Res. 2013 36 6 759 767 10.1007/s12272‑013‑0051‑4 23539311
    [Google Scholar]
  76. Caliceti C. Rizzo P. Cicero A.F.G. Potential benefits of berberine in the management of perimenopausal syndrome. Oxid. Med. Cell. Longev. 2015 2015 1 9 10.1155/2015/723093 25785174
    [Google Scholar]
  77. Wu J. Nakashima S. Shigyo M. Yamasaki M. Ikuno S. Morikawa A. Takegami S. Nakamura S. Konishi A. Kitade T. Matsuda H. Antihypertensive constituents in Sanoshashinto. J. Nat. Med. 2020 74 2 421 433 10.1007/s11418‑019‑01382‑9 31894475
    [Google Scholar]
  78. Song D. Hao J. Fan D. Biological properties and clinical applications of berberine. Front. Med. 2020 14 5 564 582 10.1007/s11684‑019‑0724‑6 32335802
    [Google Scholar]
  79. Liu X. Zhang X. Ye L. Yuan H. Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model. Biomed. Pharmacother. 2016 79 222 230 10.1016/j.biopha.2016.02.015 27044832
    [Google Scholar]
  80. Feng M. Zou Z. Zhou X. Hu Y. Ma H. Xiao Y. Li X. Ye X. Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE−/− mice. Int. Immunopharmacol. 2017 43 195 202 10.1016/j.intimp.2016.12.001 28024280
    [Google Scholar]
  81. Cheng W.-E. Chang M.Y. Wei J.-Y. Chen Y.-J. Maa M.-C. Leu T.-H. Berberine reduces toll-like receptor-mediated macrophage migration by suppression of Src enhancement. Eur. J. Pharmacol. 757 2015 1 10 10.1016/j.ejphar.2015.03.013
    [Google Scholar]
  82. Li G. Wang X. Jiang T. Gong J. Niu L. Li N. Berberine prevents intestinal mucosal barrier damage during early phase of sepsis in rat through the toll-like receptors signaling pathway. Korean J. Physiol. Pharmacol. 2015 19 1 1 7 10.4196/kjpp.2015.19.1.1 25605990
    [Google Scholar]
  83. Warowicka A. Nawrot R. Goździcka-Józefiak A. Antiviral activity of berberine. Arch. Virol. 2020 165 9 1935 1945 10.1007/s00705‑020‑04706‑3 32594322
    [Google Scholar]
  84. Pang Y.N. Liang Y.W. Feng T.S. Zhao S. Wu H. Chai Y.S. Lei F. Ding Y. Xing D.M. Du L.J. Transportation of berberine into HepG2, HeLa and SY5Y cells: A correlation to its anti-cancer effect. PLoS One 2014 9 11 e112937 10.1371/journal.pone.0112937 25402492
    [Google Scholar]
  85. Varghese F.S. Thaa B. Amrun S.N. Simarmata D. Rausalu K. Nyman T.A. Merits A. McInerney G.M. Ng L.F.P. Ahola T. The antiviral alkaloid berberine reduces chikungunya virus-induced mitogen-activated protein kinase signaling. J. Virol. 2016 90 21 9743 9757 10.1128/JVI.01382‑16 27535052
    [Google Scholar]
  86. Shin H.B. Choi M.S. Yi C.M. Lee J. Kim N.J. Inn K.S. Inhibition of respiratory syncytial virus replication and virus-induced p38 kinase activity by berberine. Int. Immunopharmacol. 2015 27 1 65 68 10.1016/j.intimp.2015.04.045 25939536
    [Google Scholar]
  87. Kim S.Y. Kim H. Kim S.W. Lee N.R. Yi C.M. Heo J. Kim B.J. Kim N.J. Inn K.S. An effective antiviral approach targeting hepatitis B virus with NJK14047, a novel and selective biphenyl amide p38 mitogen-activated protein kinase inhibitor. Antimicrob. Agents Chemother. 2017 61 8 e00214-17 10.1128/AAC.00214‑17 28559272
    [Google Scholar]
  88. Gao R. Lu Y. Zhang W. Zhang Z. The application of berberine in fibrosis and the related diseases. Am. J. Chin. Med. 2024 52 3 753 773 10.1142/S0192415X24500307 38716621
    [Google Scholar]
  89. Effects of berberine in reducing abdominal visceral adipose tissue among individuals with obesity and NAFLD (BRAVO). NCT05647915 2022
  90. Nejati L. Berberine and non-alcoholic fatty liver disease (NAFLD) (NAFLD). NCT04049396 2019
  91. Berberine effects on clinical symptoms and metabolic disturbance in patients with schizophrenia. NCT03548155> 2023
  92. Bezafibrate plus berberine in mixed dyslipidemia. NCT02548832 2023
  93. Effect of probiotics or berberine in hepatic steatosis markers, cardiometabolic and microbiotic profile in NAFL. NCT05523024 2022
  94. Berberine and cinnamon in management of diabetes. NCT05570357 2024
  95. Helicobacter pylori eradication with berberine plus amoxicillin triple therapy versus bismuth-containing quadruple therapy. NCT04697186 2023
  96. Combination of danazole with berberine in the treatment of ITP. NCT03909763 2020
  97. Effect of berberine for endothelial function and intestinal microflora in patients with coronary artery disease. NCT04434365 2020
  98. Effects of berberine plus inulin on diabetes care in patients with LADA. NCT04698330 2022
  99. Effects of berberine hydrochloride and bifidobacterium in prediabetes prevention and treatment. NCT02082756 2018
  100. Therapeutic effects of berberine in patients with type 2 diabetes. NCT00425009 2007
  101. Berberine treat metabolic syndrome in schizophrenia. NCT03251716 2018
  102. Pharmacological profile of different berberine formulations, and effects on blood sugar levels. NCT05370261 2023
  103. Efficacy and safety of berberine in the treatment of diabetes with dyslipidemia. NCT00462046 2007
  104. Effect of gamma-cyclodextrin on the bioavailability of berberine. NCT04918667 2023
  105. Helicobacter pylori eradication with berberine quadruple therapy versus clarithromycin quadruple therapy. NCT02633930 2017
  106. Study on the efficacy and safety of berberine-containing triple therapy in Helicobacter pylori first-line eradication. NCT05014334 2023
  107. Yang J-K. Berberine hyperglycemic clamp (BBR HC). NCT03972215 2023
  108. Berberine as adjuvant treatment for schizophrenia patients (BER). NCT02983188 2021
  109. Impact of OCT1 and CYP2D6 genotypes on pharmacokinetics of berberine in healthy volunteers (BERKI-1). NCT05463003 2023
  110. Anti-platelet effect of berberine in patients after percutaneous coronary intervention (APLABE-PCI). NCT03378934 2022
  111. The absorption of bioactive berberine in human. NCT03438292 2021
  112. Gao X. Role of pioglitazone and berberine in treatment of non-alcoholic fatty liver disease.. NCT00633282 2012
  113. Berberine and altered fasting glucose. NCT05031715 2022
  114. Effect of berberine versus metformin on glycemic control, insulin sensitivity and insulin secretion in prediabetes. NCT03029390 2023
  115. Endoscopic and microbiological assessment of the effect of carvedilol combined with berberine on gov in cirrhosis (CABER). NCT04543643 2021
  116. Bioavailability of berberine and dihydroberberine and their impact on glycemia (BBD). NCT05021341 2021
  117. Treatment benefits of berberine supplementation for women with PCOS. NCT05480670 2023
  118. Effects of berberine on preventing cardiovascular disease and diabetes mellitus (ABCD). NCT05749874 2023
  119. Berberine chloride in preventing colorectal cancer in patients with ulcerative colitis in remission. NCT02365480 2021
  120. Berberine, chlorogenic acid and tocotrienols in menopause-associated dyslipidemia. NCT03019263 2018
  121. Berberine, curcumin, inositol, banaba and chromium picolinate in patients with fasting dysglycemia. NCT04107987 2019
  122. Effect of berberine on metabolic syndrome, efficacy and safety in combination with antiretroviral therapy in PLWH. (BERMESyH). NCT04860063 2021
  123. Berberine prevent contrast-induced nephropathy in patients with diabetes. NCT02808351 2022
  124. Evaluating the tolerability and effects of berberine on major metabolic biomarkers: A pilot study. NCT03976336 2024
  125. A research of berberine hydrochloride to prevent colorectal adenomas in patients with previous colorectal cancer. NCT03281096 2022
  126. Combination of curcumin and berberine therapy in the treatment of post acute diverticulitis (SUDD). NCT05596214 2023
  127. Primary chemoprevention of familial adenomatous polyposis with berberine hydrochloride. NCT03333265 2022
  128. Study of berberine hydrochloride in prevention of colorectal adenomas recurrence. NCT02226185 2019
  129. Helicobacter rescue therapy with berberine plus amoxicillin quadruple therapy versus tetracycline plus furazolidone quadruple therapy. NCT03609892 2019
  130. The BANGALORE study; Combination of berberine, lipoic acid, and picrorhiza (CAR-191). NCT01696448 2014
  131. Berberine effect on cytokine, CRP, metabolic disturbance as an adjunctive therapy in schizophrenia patients. NCT02936414 2018
  132. Effect of BGG on glucose metabolism and other markers of metabolic syndrome (Glucogold). NCT02834078 2016
  133. Tang Y. Cardiovascular diseases and diabetes prevention programme in metabolic syndrome (CDPP) (CDPP). NCT05105321 2021
  134. Metabolic and cardiovascular effects of armolipid plus in subjects with metabolic syndrome (ARMP-11). NCT02295176 2015
  135. Berberine and polycystic ovary syndrome. NCT04932070 2021
  136. Effectiveness and safety of berberine hydrochloride and bifidobacterium in people with abnormal glucose level. NCT03330184 2021
  137. The effect of berberine on intestinal function and inflammatory mediators in severe patients with Covid-19 (BOIFIM). NCT04479202 2020
  138. Comparison of berberine and metformin for the treatment for ms in schizophrenia patients. NCT03708549 2022
  139. Kumar S. Saharan R. Saini V. Saini A. Gallic acid: A wonderful remedy in medicinal field. Curr. Tradit. Med. 10.2174/0122150838266828231005055236
    [Google Scholar]
  140. Devi V. Deswal G. Dass R. Chopra B Kriplani P. Grewal A.S. Dhingra A.K. Hemorrhoid Disease: A review on treatment, clinical research and patent data. Infect. Disord. Drug Targets 23 6 e270423216271 2023 10.2174/1871526523666230427115436 37106517
    [Google Scholar]
  141. Devi V. Deswal G. Dass R. Chopra B. Kriplani P. Grewal A.S. Guarve K. Dhingra A.K. Therapeutic potential and clinical effectiveness of quercetin: A dietary supplement. Recent Adv. Food Nutr. Agric. 15 1 13 32 2024 10.2174/012772574X269376231107095831
    [Google Scholar]
  142. Colman J. Combinations of berberine, artemisinin, loperamide and their derivatives to treat malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses. US Patent 20130071474A1 2013
  143. Davies G. Yueshan H. Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs. US Patent 20110281852A1 2011
  144. Nishina Y. Matsumoto E. Kiyobayashi Y. Berberine-containing aqueous composition. JP Patent 2008024700A 2008
  145. Xie Y. Tang Y. Zhao Z. Zhuo C. Wu D. Fenofibric acid salt with berberine or its analogues, crystalline forms, methods of preparation, and applications thereof. US Patent 10577379B1 2020
  146. Christine D. Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders. WO Patent 2004093876A2 2005
  147. Jia B. Berberine double salt and preparation method and application thereof. CN Patent 105294676A 2017
  148. Xie Y. Zhao Z. Zheng Y. Hu L. Chen Z. Wan F. Wu D. Purification method and crystal form of berberine or berberine salt. CN Patent 111205285B 2021
  149. Wu K. Application of high-solubility berberine in preparing medicine. CN Patent 1771944A 2006
  150. David Xiang Y. Zhicheng X. Berberine alkaloid formulations in the prevention and/or treatment of infectious disease. US Patent 20210329946A1 2021
  151. Su X. Berberine and fenofibrate pharmaceutical composition and use thereof. CN Patent 105560233A 2018
  152. Su X. Berberine and simvastatin pharmaceutical composition and use thereof. CN Patent 105560232A 2017
  153. Yong K. Kai Z. Su X. Zhu Y. Zhou L. Lang G. Wang Y. Oral medicine composition consisting of berberine and melbine, and preparation method thereof. CN Patent 103271907B 2014
  154. Deng Y. Yang X. Zhang X. Berberine liposome and preparation method thereof. CN patent 102475682B 2013
  155. Wang Y. Andrographolide and berberine combination and application thereof. CN Patent 102151260B 2012
  156. Guang N. Li X. Zhang Y. Jie H. Gu W. Zhi Z. Wang W. Li H. Na Z. Gu S. Use of berberine in treating metabolism complex. CN Patent 101219141A 2008
  157. Shang S. Min X. Li Y. Lan S. Method for synthesizing berberine citrate. CN101948469B 2012
  158. Han Y. Zheng X. Xin C. Tea tree oil-berberine antibacterial composite suspension emulsion and preparation method thereof. CN Patent 105638758A 2018
  159. Jiang M. Wu Y. Zhu X. Oral pharmaceutical composition of diacerein and berberine, and applications thereof. CN Patent 104771400A 2015
  160. He L. Zhang Y. Sulfuric acid or berberine hydrochloride multivesicular liposome and preparation method thereof. CN Patent 106361702B 2019
  161. Zhu X. Wu Y. Jiang M. Oral pharmaceutical composition of diacerein and berberine. CN patent 104771401A 2015
  162. Li X. Deng J. Qin Z. Mangiferin-berberine composition. CN Patent 101066275A 2007
  163. Jun Y. Medicine composition of berberine and repaglinide. CN Patent 105055413A 2015
  164. Xie X. Li Z. Shen Z. Wang T. Pharmaceutical composition utilizing berberine to inhibit cancer stem cell growth or cancer cell metastasis, and application thereof. CN Patent 102824344A 2012
  165. Heng Z. Lao X. Zhou D. Yu Y. New application of using berberine as metal beta-lactamase inhibitor. CN Patent 105232548A 2018
  166. Shuai H. Li L. Yuan F. Li L. One kind is without palatability high content berberine sulphate oral liquid and preparation method thereof. CN Patent 106729739A 2017
  167. Wang C. Sun W. Zheng F. Lu C. Zhu Z, Mao L.Z. Zhang H. Zhu M. Rhubarb yellow berberine ion-pair compound, preparation method and application. CN Patent 103319479B 2015
  168. Hsieh H.-M. Lee C.-Y. Shen C.C. Wang T.-C. Berberine-containing pharmaceutical composition for inhibiting cancer stem cell growth or carcinoma metastasis and application thereof. US Patent 20150320738A 2015
  169. Bo J. Wang S. Na W. Liu X. Shuang X. A kind of Berberine hydrochloride takes orally pellet xerogel and its preparation method and application. CN Patent 106511260B 2019
  170. Huang Z. Gu L. Yan M. 9-N-substituted berberine derivatives as well as preparation method and use as anti-cancer drugs. CN Patent 101255158B 2010
  171. Ye X. Li X. Long chain alkyl berberine salt derivative, synthetic method and use. CN Patent 101104618B 2010
  172. Chen Y. Yi L. Chen J. Gao J. Qian C. Wen C. Berberine organic acid salt, berberine organic acid salt inclusion compound and preparation methods thereof. CN Patent 101935319A 2011
  173. Tseng P.-Y. Brown C. O. Therapeutic uses of berberine formulations. US Patent 10213418B2 2019
  174. Cui Y. Zhang Y. Berberine cyclodextrin inclusion compound, preparation thereof and preparation method. CN Patent 101461949B 2011
  175. Liu S. Qi L. Berberine hydrochloride eutectic crystal, preparation method and application thereof. CN Patent 108558861B 2021
  176. Ji Y.C.Y. Synthesis method and application of taxol-berberine nano-drug. CN Patent 110251685B 2022
  177. Han Z. Berberine hydrochloride taste-masked pellet, and preparation thereof. CN Patent 104997735A 2015
  178. Wang P.-L. Berberine formulations and uses thereof. US Patent 9427432B2 2016
  179. Wu H. Li J. Bu C. Compound preparation of berberine hydrochloride. CN Patent 101467999A 2009
  180. Wave D. Berberine-phenylacetic acid derivative, its pharmaceutically acceptable salt and synthetic method. CN Patent 102229607A 2011
  181. Yang L. Guanhua D. Junzi C. Shiying Y. Eutectic compound of berberine hydrochloride and fumaric acid, preparation method, composition and application thereof. CN Patent 110041326B 2022
  182. Ya S. Tan J. Zhou Z. Berberine hydrochloride granule for masking flavor and its preparation. CN Patent 1273133C 2006
  183. Aneta B. Jiri L. Manufacturing method of oral dosage form containing berberine, oral dosage form containing berberine and use thereof. WO Patent 2019024949A1 2019
  184. Yang S. Mei X. Li X. Berberine hydrochloride solid lipid nano preparation and preparation method thereof. CN Patent 102949375B 2015
  185. Hu L. Jia L. 13, 13a- dihydro berberine derivant and pharmaceutical composition. CN Patent 101153039B 2010
  186. Teng H. Wei W. Zhe L. Mangiferin-berberine salt, manufacturing method and use thereof. CN Patent 102753185B 2014
  187. Liu L. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof. AU Patent 2019222911B2 2021
  188. Gabriele J. Baranowski D. Buchanan B. Zuccolo J. Teris M. Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions. US Patent 20180235870A1 2018
  189. Weng W. Huang J. Shenteng Q.B. Zhang J. Xu H. Guo J. Aliphatic organic acid salt of berberine type alkaloid and preparation method and usage thereof. CN Patent 101113149B 2011
  190. Tang J. Fan X. A kind of Berberine electrostatic complexes and preparation method thereof. CN102702190B 2016
  191. Teng H. Wu W. Zhang J.Z. Lin Z. Mangiferin-6-O-berberine salt and preparation method and use thereof. US Patent 10285969B2 2019
/content/journals/npj/10.2174/0122103155324599241028163050
Loading
Exploring Pharmacological Mechanisms, Clinical Trials and Patent Landscapes of Berberine: A Review
Bentham Science Publishers ; https://doi.org/10.2174/0122103155324599241028163050
/content/journals/npj/10.2174/0122103155324599241028163050
/content/journals/npj/10.2174/0122103155324599241028163050
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: neuro-effectiveness activity ; caner ; patent study ; source ; Diabetes mellitus ; clinical data

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test